Development and stability of semisolid preparations based on a supercritical CO2 Arnica extract

Journal of Pharmaceutical and Biomedical Analysis

Volumn 41, Issue 2, 2006, Pages 449-454

  Bilia, Anna Rita ^a   Bergonzi, Maria Camilla ^a   Mazzi, Giovanni ^a   Vincieri, Franco Francesco ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Arnica montana L. (Asteracee) supercritical CO2 extract; In vitro and in vivo tests; Semisolid preparations; Sesquiterpenes

Indexed keywords

ANPHYPHIL; ARNICA MONTANA EXTRACT; CARBON DIOXIDE; CETOMACROGOL; HYDROXYETHYLCELLULOSE; POLYSORBATE 60; POLYSORBATE 80; SEPIGEL; SESQUITERPENE LACTONE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARNICA MONTANA; ARTICLE; CONTROLLED STUDY; CREAM; DRUG DETERMINATION; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; EMULSION; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MASS SPECTROMETRY; NONHUMAN; NORMAL HUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

ADMINISTRATION, CUTANEOUS; ADULT; ARNICA; CETOMACROGOL; CHROMATOGRAPHY, SUPERCRITICAL FLUID; DRUG STABILITY; EMULSIONS; EXCIPIENTS; FEMALE; HUMANS; PERMEABILITY; PLANT EXTRACTS; POLYSORBATES; SESQUITERPENES; SKIN ABSORPTION; SURFACE-ACTIVE AGENTS;

EID: 33646410078     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2005.12.024     Document Type: Article

References (15)

1. Pinchon T.M., and Pinkas M. Le genre arnica. Plant Med. Phytother. 22 (1988) 125-156
2. Macêdo S.B., Ferreira L.R., Perazzo F.F., and Carvalho J.C.T. Homeopathy 93 (2004) 84-87
3. European Pharmacopoeia, 3rd ed., Council of Europe, 2000, pp. 396-398.
4. Willuhn G., and Arnikablüten. In: Wichtl M. (Ed). Teedrogen und Phytopharmak. 2nd ed. (1989), Wissenschaftlicher Werlagsgesellschaft GmbH, Stuttgard 65-69
5. Bilia A.R., Bergonzi M.C., Mazzi G., and Vincieri F.F. J. Pharm. Biomed. Anal. 30 (2002) 321-330
6. Bergonzi M.C., Bilia A.R., Casiraghi A., Cilurzo F., Minghetti P., Montanari L., and Vincieri F.F. Pharmazie 60 (2005) 36-38
7. ICH Working Group, Stability Testing of New Drug Substances and Products, Guideline Q1A, 1994.
8. European Pharmacopoeia, 4th ed., Council of Europe, 2003, pp. 3899-3900.
9. FDA, Guidance for Industry, Topical Dermatological Drug Product NDAs and ANDAs-In Vivo Bioavailability, Bioequivalence, In Vitro Release and Associated Studies, 1998.
10. Wagner S., Suter A., and Merfort I. Planta Medica 70 (2004) 897-903
11. National Formulary of the Italian Pharmacopoeia, 1988.
12. Dupuis D., Rougier A., Roguet R., and Lotte C. Br. J. Dermatol. 115 (1986) 233-238
13. Gean C.J., Tur E., Maibach H.I., and Guy R.H. Arch. Dermatol. Res. 281 (1989) 95-98
14. Kompaore F., Dupon C., and Marty J.P. Int. J. Cosmet. 13 (1991) 293-302
15. Panigrahi L., Pattnaik S., and Ghosal S.K. AAPS Pharm. Sci. Technol. 6 (2005) E167-E173